3 papers in the library · 8 citations · publishing 2025
ACS Pharmacology & Translational Science March 14, 2025 Hongyuan Li, Xiaohui Wang 5 citations
Psychedelic experiences can provide transformative perspectives on dying, potentially easing existential distress and improving quality of life for the terminally ill. Their growing recognition in palliative care, therapy, and spiritual exploration may revolutionize end-of-life care.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) May 1, 2025 Yuanpeng Li, Hongyuan Li, Hongshuang Wang et al. 3 citations
Amphetamine-type stimulants (ATS) and their analogs can be rapidly evaluated using the roundworm Caenorhabditis elegans. In a swimming-induced paralysis assay, worms exposed to amphetamine, methamphetamine, MDMA, and their enantiomers showed distinct behavioral responses depending on their genetic makeup. The effects depended on dopaminergic and serotonergic pathways, specifically the DOP-3 and SER-4 receptors. The assay also distinguished between chiral forms of ATS, and meta-R amphetamines produced stronger effects than ortho-R and para-R analogs. This method offers a cost-effective, high-throughput way to assess the activity and toxicity of new psychoactive substances.
Molecular Psychiatry December 1, 2025 Yuanpeng Li, Hongyuan Li, Hongshuang Wang et al.
Psychedelics, especially psilocybin, show promise as treatments for substance use disorders (SUDs) including alcohol, nicotine, heroin, and cocaine. They may work by disrupting maladaptive neural circuits, promoting neuroplasticity, and enabling psychological insights that address root causes. Clinical trials indicate psilocybin-assisted therapy can significantly reduce substance use and improve mental health outcomes. However, legal barriers, safety concerns, and the need for more rigorous research remain. The outlook is cautiously optimistic, with potential to transform SUD therapy.